ProtOS

Company Overview

Snapshot

Founded in January 2023 by Yossi Pollak and Ofer Springer, ProtOS operates with 1–10 employees. The company has secured funding across one round from two investors, with Fresh Fund identified as a lead investor.

Business overview

ProtOS is an AI-first protein design company focused on developing therapeutics for previously undruggable diseases. The company leverages proprietary AI models to create novel bio-therapeutics that precisely interact with proteins-of-interest, extending beyond the capabilities of small molecules and antibodies. Its SHRED platform utilizes foundation models to design de-novo AI-proteins for highly specific and effective degradation of challenging targets, offering advancements over existing PROTAC and Molecular-Glue approaches within the Pharma & Medical Biotechnology sector.

Company Intelligence Q&A

When was ProtOS founded?

ProtOS was founded in January 2023 by Yossi Pollak and Ofer Springer.

What is the primary focus of ProtOS?

ProtOS is an AI-first protein design company developing therapeutics to treat undruggable diseases by leveraging proprietary AI models to create novel bio-therapeutics.

What is the SHRED platform?

The SHRED platform is a robust therapeutic platform developed by ProtOS that uses foundation models to design de-novo AI-proteins for the specific and effective degradation of undruggable targets.

Which investors participated in the September 2025 funding round?

In September 2025, ProtOS secured funding from Fresh Fund and Good Company VC. Fresh Fund was a lead investor in this round.

What is the employee count for ProtOS?

ProtOS currently has 1–10 employees.